Bleak Days for This Big Pharma

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Bleak. That's probably the best word to describe last week's third-quarter earnings results from big pharmaceutical company Bristol-Myers Squibb (NYSE: BMY  ) . This was one depressing third quarter. The best news for the quarter is that it's over. 

Down, down and down
What went wrong? The list is pretty long, but here are the low points.

Net sales dropped 30% compared with the third quarter of 2011. Falling off the patent cliff hurts. Bristol lost patent exclusivity for both Plavix and Avapro/Avalide earlier this year, resulting in a restructuring of its partnership for the drugs with Sanofi (NYSE: SNY  ) . 

Bristol reported GAAP earnings per share of $0.56 in the third quarter of 2011. The company lost $0.43 per share in the same quarter this year. Its non-GAAP earnings per share also fell 33% to $0.41.

The company took a $1.8 billion impairment charge with its discontinuation of BMS-986094. The hepatitis C drug was abandoned after one of the patients in a phase 2 trial suffered a heart attack.

What about guidance for the full year? Down also. Bristol lowered its GAAP earnings guidance from a range of $1.78 to $1.88 to a range of $0.95 to $1.05. 

Other than that ...
After all that bad news, looking for a silver lining might seem a little like the old joke: "Other than that, Mrs. Lincoln, how was the play?" However, there actually are a few reasons for Bristol-Myers Squibb to be optimistic about the future.

Several of the company's current drugs continue to experience strong growth. Sales for Yervoy surged 48% in the third quarter compared with last year. Onglyza, a diabetes drug marketed in partnership with AstraZeneca (NYSE: AZN  ) , saw sales jump by 40%. Orencia sales were up 32%.

Bristol completed its acquisition of Amylin during the third quarter. This beefs up the company's diabetes drug portfolio with the addition of Byetta and Bydureon. The transaction also included a $1.7 billion payout to Lilly (NYSE: LLY  ) to end its collaboration on the drugs with Amylin. 

The company looks forward to potentially more good news in first quarter of 2013. The FDA set March 17 as the decision date for Eliquis. Bristol partnered with Pfizer (NYSE: PFE  ) on the drug that targets prevention of strokes in atrial fibrillation.

Bleak to bright?
These pieces of good news bode well for Bristol-Myers Squibb's future. Investors should find other reasons to like the company also. Bristol sits on $2.9 billion in cash, equivalents, and short-term investments. It has another $3.7 billion in long-term securities. The company's dividend yield currently stands at 4%.

Despite Bristol's bad third quarter, its stock trades near the middle of its 2012 range. Now could be a good time for investors to look at buying shares. Bristol certainly has seen bleak days recently, but its future over the long run should still be bright.

If you're interested in other high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here to discover the winners we've picked.

Keith Speights has no positions in the stocks mentioned above. The Motley Fool owns shares of AstraZeneca. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 31, 2012, at 1:56 AM, chris293 wrote:

    My first shares of BMY were brought in the late 80's. Naturally some people said to sell like they always do then. Timing does matter, I did sell when I needed to at a good profit most of the time. The dividend then was 3.9 or 4% and still is. Yes I own long and I may get more, but I don't show my hand before I call. The good points of this article is how BMY has a good finanical base.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2084824, ~/Articles/ArticleHandler.aspx, 10/21/2016 8:08:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:01 PM
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
AZN $30.72 Down -0.28 -0.90%
AstraZeneca CAPS Rating: ****
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****